Zdrowie i gospodarka · 17/02/2021
FDA Clears Nimodipine for Potential Approval via Abbreviated New Drug Applications
The FDA has determined that NYMALIZE (nimodipine) oral solution, 3 mg/mL, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications (ANDAs) for this product.
Source: Federal Register — Food and Drug AdministrationOpen original release →